Kelley RK, Bridgewater J, Gores GJ, Zhu AX. Systemic therapies for intrahepatic cholangiocarcinoma. J Hepatol. 2020;72:353–63.

Article  CAS  PubMed  Google Scholar 

Ali PI, Saleem K, Aboul-Enein H, Rather M, Imran D. Social Aspects of Cancer Genesis.

Ali I, Alsehli M, Scotti L, Tullius Scotti M, Tsai S-T, Yu R-S, Hsieh MF, Chen J-C. Progress in polymeric nano-medicines for theranostic cancer treatment. 2020;12:598.

Sirica AE, Gores GJ. Desmoplastic stroma and cholangiocarcinoma: clinical implications and therapeutic targeting. Hepatology. 2014;59:2397–402.

Article  PubMed  Google Scholar 

Sirica AE, Gores GJ, Groopman JD, Selaru FM, Strazzabosco M, Wei Wang X, Zhu AX. Intrahepatic cholangiocarcinoma: continuing challenges and translational advances. Hepatology. 2019;69:1803–15.

Article  PubMed  Google Scholar 

Ali I, Lone MN, Alothman ZA, Alwarthan A. Insights into the pharmacology of new heterocycles embedded with oxopyrrolidine rings: DNA binding, molecular docking, and anticancer studies. J Mol Liq. 2017;234:391–402.

Article  CAS  Google Scholar 

Lamarca A, Edeline J, Goyal L. How I treat biliary tract cancer. ESMO Open. 2022;7:100378.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Høgdall D, Lewinska M, Andersen JB. Desmoplastic tumor microenvironment and immunotherapy in cholangiocarcinoma. Trends Cancer. 2018;4:239–55.

Article  PubMed  Google Scholar 

Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control. 2017;24:1073274817729245.

Article  PubMed  PubMed Central  Google Scholar 

Ali I, Wani WA, Haque A, Saleem K. Glutamic acid and its derivatives: candidates for rational design of anticancer drugs. Future Med Chem. 2013;5:961–78.

Article  CAS  PubMed  Google Scholar 

Moris D, Palta M, Kim C, Allen PJ, Morse MA, Lidsky ME. Advances in the treatment of intrahepatic cholangiocarcinoma: an overview of the current and future therapeutic landscape for clinicians. CA Cancer J Clin. 2023;73:198–222.

Article  PubMed  Google Scholar 

Ali I, Wani WA, Saleem K, Hsieh M-F. Anticancer metallodrugs of glutamic acid sulphonamides: in silico, DNA binding, hemolysis and anticancer studies. RSC Adv, 4:29629–41.

Ali I, Wani WA, Khan A, Haque A, Ahmad A, Saleem K, Manzoor N. Synthesis and synergistic antifungal activities of a pyrazoline based ligand and its copper(II) and nickel(II) complexes with conventional antifungals. Microb Pathog. 2012;53:66–73.

Article  CAS  PubMed  Google Scholar 

Ding HX, Liu KK, Sakya SM, Flick AC, O’Donnell CJ. Synthetic approaches to the 2011 new drugs. Bioorg Med Chem. 2013;21:2795–825.

Article  CAS  PubMed  Google Scholar 

Ali PI. Synthesis, DNA binding, hemolytic and anticancer assays of curcumin I based ligands and their ruthenium (III) complexes. Med Chem Res. 2013;22:1386–98.

Article  CAS  Google Scholar 

Fabris L, Perugorria MJ, Mertens J, Björkström NK, Cramer T, Lleo A, Solinas A, Sänger H, Lukacs-Kornek V, Moncsek A, et al. The tumour microenvironment and immune milieu of cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):63–78.

Article  PubMed  PubMed Central  Google Scholar 

Sharma V, Letson J, Furuta S. Fibrous stroma: driver and passenger in cancer development. Sci Signal. 2022;15:eabg3449.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kajiyama K, Maeda T, Takenaka K, Sugimachi K, Tsuneyoshi M. The significance of stromal desmoplasia in intrahepatic cholangiocarcinoma: a special reference of ‘scirrhous-type’ and ‘nonscirrhous-type’ growth. Am J Surg Pathol. 1999;23:892–902.

Article  CAS  PubMed  Google Scholar 

Chang P, Cheng CT, Wu RC, Chung YH, Chiang KC, Yeh TS, Liu CY, Chen MH, Chen MH, Yeh CN. Nab–paclitaxel is effective against intrahepatic cholangiocarcinoma Vi a disruption of desmoplastic stroma. Oncology Letters.

Nicolás-Boluda A, Vaquero J, Laurent G, Renault G, Bazzi R, Donnadieu E, Roux S, Fouassier L, Gazeau F. Photothermal depletion of cancer-associated fibroblasts normalizes tumor stiffness in desmoplastic cholangiocarcinoma. ACS Nano. 2020;14:5738–53.

Article  PubMed  Google Scholar 

Gao Y, Liu S, Liu H, Ge H, Zhang M, Zhao C, Gong Y, Zhang X, Wang C, Sun X, Wu Z. Application of oxygen vacancy defects in enhanced anti-cancer nanomedicine. Sci China Chem. 2023;66:2492–512.

Article  CAS  Google Scholar 

Chen YP, Yin JH, Li WF, Li HJ, Chen DP, Zhang CJ, Lv JW, Wang YQ, Li XM, Li JY, et al. Single-cell transcriptomics reveals regulators underlying immune cell diversity and immune subtypes associated with prognosis in nasopharyngeal carcinoma. Cell Res. 2020;30:1024–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Obradovic A, Chowdhury N, Haake SM, Ager C, Wang V, Vlahos L, Guo XV, Aggen DH, Rathmell WK, Jonasch E, et al. Single-cell protein activity analysis identifies recurrence-associated renal tumor macrophages. Cell. 2021;184:2988–e30052916.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Chatterjee M, Borst O, Walker B, Fotinos A, Vogel S, Seizer P, Mack A, Alampour-Rajabi S, Rath D, Geisler T, et al. Macrophage migration inhibitory factor limits activation-induced apoptosis of platelets via CXCR7-dependent akt signaling. Circ Res. 2014;115:939–49.

Article  CAS  PubMed  Google Scholar 

Agarwal R, D’Souza T, Morin PJ. Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res. 2005;65:7378–85.

Article  CAS  PubMed  Google Scholar 

Chen ZW, Kang FP, Xie CK, Liao CY, Li G, Wu YD, Lin HY, Zhu SC, Hu JF, Lin CF, et al. A novel trojan horse nanotherapy strategy targeting the cPKM-STMN1/TGFB1 axis for effective treatment of intrahepatic cholangiocarcinoma. Adv Sci (Weinh). 2023;10:e2303814.

Article  PubMed  Google Scholar 

Mao X, Xu J, Wang W, Liang C, Hua J, Liu J, Zhang B, Meng Q, Yu X, Shi S. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20:131.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Li C, Teixeira AF, Zhu HJ, Ten Dijke P. Cancer associated-fibroblast-derived exosomes in cancer progression. Mol Cancer. 2021;20:154.

Article  PubMed  PubMed Central  Google Scholar 

Zhao M, Ma J, Li M, Zhang Y, Jiang B, Zhao X, Huai C, Shen L, Zhang N, He L, Qin S. Cytochrome P450 enzymes and drug metabolism in humans. 2021, 22:12808.

Upatham ES, Viyanant V. Opisthorchis viverrini and opisthorchiasis: a historical review and future perspective. Acta Trop. 2003;88:171–6.

Article  CAS  PubMed  Google Scholar 

Raggi C, Taddei ML, Rae C, Braconi C, Marra F. Metabolic reprogramming in cholangiocarcinoma. J Hepatol. 2022;77:849–64.

Article  CAS  PubMed  Google Scholar 

Katoh M, Nakagama H. FGF receptors: cancer biology and therapeutics. Med Res Rev. 2014;34:280–300.

Article  CAS  PubMed  Google Scholar 

Kim B, Kim Y, Cho JY, Lee KA. Identification of potential genomic alterations using pan-cancer cell-free DNA next-generation sequencing in patients with gastric Cancer. Ann Lab Med. 2024;44:164–73.

Article  CAS  PubMed  Google Scholar 

Boerner T, Drill E, Pak LM, Nguyen B, Sigel CS, Doussot A, Shin P, Goldman DA, Gonen M, Allen PJ, et al. Genetic determinants of outcome in intrahepatic cholangiocarcinoma. Hepatology. 2021;74:1429–44.

Article  CAS  PubMed  Google Scholar 

Liu Q, Zhang J, Guo C, Wang M, Wang C, Yan Y, Sun L, Wang D, Zhang L, Yu H et al. Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies. Cell, 187:184–e203128.

Goyal L, Kongpetch S, Crolley VE, Bridgewater J. Targeting FGFR inhibition in cholangiocarcinoma. Cancer Treat Rev. 2021;95:102170.

Article  CAS  PubMed  Google Scholar 

Xia X, Li X, Li F, Wu X, Zhang M, Zhou H, Huang N, Yang X, Xiao F, Liu D et al. A novel tumor suppressor protein encoded by circular AKT3 RNA inhibits glioblastoma tumorigenicity by competing with active phosphoinositide -dependent Kinase-1. Mol Cancer, 18.

Krook MA, Lenyo A, Wilberding M, Barker H, Dantuono M, Bailey KM, Chen HZ, Reeser JW, Wing MR, Miya J, et al. Efficacy of FGFR inhibitors and combination therapies for acquired resistance in FGFR2-fusion cholangiocarcinoma. Mol Cancer Ther. 2020;19:847–57.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Goyal L, Meric-Bernstam F, Hollebecque A, Valle JW, Morizane C, Karasic TB, Abrams TA, Furuse J, Kelley RK, Cassier PA, et al. futibatinib for FGFR2-rearranged intrahepatic cholangiocarcinoma. N Engl J Med. 2023;388:228–39.

Article  CAS  PubMed  Google Scholar 

Maksym RB, Tarnowski M, Grymula K, Tarnowska J, Wysoczynski M, Liu R, Czerny B, Ratajczak J, Kucia M, Ratajczak MZ. The role of stromal-derived factor-1–CXCR7 axis in development and cancer. Eur J Pharmacol. 2009;625:31–40.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tan SH, Barker N. Stemming colorectal cancer growth and metastasis: HOXA5 forces cancer stem cells to differentiate. Cancer Cell. 2015;28:683–5.

Article  PubMed  Google Scholar 

Liao Y, Wang C, Yang Z, Liu W, Yuan Y, Li K, Zhang Y, Wang Y, Shi Y, Qiu Y, et al. Dysregulated Sp1/miR-130b-3p/HOXA5 axis contributes to tumor angiogenesis and progression of hepatocellular carcinoma.